Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 334

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Open access
Bastien, Roy RL, Rodríguez-Lescure, Álvaro, Ebbert, Mark TW, Prat, Aleix, Munárriz, Blanca, Rowe, Leslie, Miller, Patricia, Ruiz-Borrego, Manuel, Anderson, Daniel, Lyons, Bradley, Álvarez, Isabel, Dowell, Tracy, Wall, David, Seguí, Miguel Ángel, Barley, Lee, Boucher, Kenneth M, Alba, Emilio, Pappas, Lisa, Davis, Carole A, Aranda, Ignacio, Fauron, Christiane, Stijleman, Inge J, Palacios, José, Antón, Antonio, Carrasco, Eva, Caballero, Rosalía, Ellis, Matthew J, Nielsen, Torsten O, Perou, Charles M, Astill, Mark, Bernard, Philip S, Martín, Miguel · 2012 · BMC Medical Genomics

Abstract

Background: Many methodologies have been used in research to identify the “intrinsic” subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. Discrepancies between these methods may lead to different treatment decisions. Methods: We used the PAM50 RT-qPCR assay to expression profile 814 tumors from the GEICAM/9906 phase III clinical trial that enrolled women with locally advanced primary invasive breast cancer. All samples were scored at a single site by IHC for estrogen receptor (ER), progesterone receptor (PR), and Her2/neu (HER2) protein expression. Equivocal HER2 cases were confirmed by chromogenic in situ hybridization (CISH). Single gene scores by IHC/CISH were compared with RT-qPCR continuous gene expression values and “intrinsic” subtype assignment by the PAM50. High, medium, and low expression for ESR1, PGR, ERBB2, and proliferation were selected using quartile cut-points from the continuous RT-qPCR data across the PAM50 subtype assignments. Results: ESR1, PGR, and ERBB2 gene expression had high agreement with established binary IHC cut-points (area under the curve (AUC) ≥ 0.9). Estrogen receptor positivity by IHC was strongly associated with Luminal (A and B) subtypes (92%), but only 75% of ER negative tumors were classified into the HER2-E and Basal-like subtypes. Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less likely to have high proliferation (11% vs 77%). Seventy-seven percent (30/39) of ER-/HER2+ tumors by IHC were classified as the HER2-E subtype. Triple negative tumors were mainly comprised of Basal-like (57%) and HER2-E (30%) subtypes. Single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis. Conclusions: The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes. Although there is high agreement between biomarker scoring by protein immunohistochemistry and gene expression, the gene expression determinations for ESR1 and ERBB2 status was more prognostic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1755-8794-5-44

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 334

Metadata

Authors
Bastien, R. R., Rodríguez-Lescure, Á., Ebbert, M. T., Prat, A., Munárriz, B., Rowe, L., Miller, P., Ruiz-Borrego, M., Anderson, D., Lyons, B., Álvarez, I., Dowell, T., Wall, D., Seguí, M. Á., Barley, L., Boucher, K. M., Alba, E., Pappas, L., Davis, C. A., Aranda, I., Fauron, C., Stijleman, I. J., Palacios, J., Antón, A., Carrasco, E., Caballero, R., Ellis, M. J., Nielsen, T. O., Perou, C. M., Astill, M., Bernard, P. S., & Martín, M.
Venue
BMC Medical Genomics
Published
2012-10-04
Volume
5
Issue
1
Pages
44-44
ISSN
1755-8794 (ISSN-L)
OpenAlex
W2119434445
Cited by
334
References
35
FWCI
8.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. https://app.cochat.ai/papers/10.1186/1755-8794-5-44
The paper
Bastien, R. R., Rodríguez-Lescure, Á., Ebbert, M. T., Prat, A., Munárriz, B., Rowe, L., Miller, P., Ruiz-Borrego, M., Anderson, D., Lyons, B., Álvarez, I., Dowell, T., Wall, D., Seguí, M. Á., Barley, L., Boucher, K. M., Alba, E., Pappas, L., Davis, C. A., . . . Martín, M. (2012). PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-5-44

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.